Quilonum retard is commonly used across domains where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations, such as bipolar disorder. Its main therapeutic application is commonly used to help with symptoms related to systemic imbalance, including managing acute or disruptive episodes and for situations involving recurrent or episodic manifestations. The medication is considered relevant in clinical settings that involve recurrent or episodic manifestations, which may include symptoms related to systemic imbalance.

Its application in clinical settings involves acute or unstable symptom patterns. This use may assist with managing symptoms that interfere with daily functioning, contributing to patient comfort during periods of heightened symptoms.

Its long-term benefit is applicable when functional stability becomes affected, and it is relevant for easing the overall symptom load associated with episodic or fluctuating manifestations. The therapeutic role of the medication can be summarized as:

“It helps address symptom clusters that may become intense or disruptive, and provides supportive relief when symptoms interfere with routine activities.”

Quick Fact: Relief for Acute Behavioral Excitement and Episodic Mood Instability

It assists with maintaining functional stability, and may help patients cope more steadily with symptom fluctuations.

Eligibility and Contraindications

The eligibility for Quilonum retard (Lithium Carbonate) is strictly defined by regulatory authorities based on a patient’s physiological health and life stage. The official criteria determine who is permitted to use the medicine and who must be excluded.

Absolute Contraindications (Must Not Use)

Use is contraindicated in patients with specific severe conditions, as these states significantly increase the risk of toxicity. The medicine must not be used by individuals diagnosed with:

• Significant renal disease or significant cardiovascular disease.
• Severe debilitation, dehydration, or sodium depletion.
• Patients concurrently receiving diuretics.

Age and Restricted Use

Use is established for adult patients and for adolescents aged 12 to 17 years for approved indications. Use in children younger than 12 years is generally not established for this extended-release formulation. Geriatric patients and those with mild to moderate renal impairment require conditional use and close monitoring.

Pregnancy and Lactation Status

Official labeling states that use during pregnancy may cause fetal harm, specifically cardiac anomalies. It is generally not recommended during lactation because the drug is excreted in human milk. Restriction applies to women of childbearing potential, requiring specific caution.

Interactions with other medicines and products

The interaction profile for Quilonum retard (lithium carbonate) is structured around two critical regulatory concerns: the risk of toxicity from altered clearance and the risk of specific neurological syndromes from combined effects. All documented interactions presented below are based strictly on official government regulatory sources.

Exposure-Modifying Interactions

Co-administration of certain medicinal products can significantly increase serum lithium levels by officially reducing its renal clearance. This documented pharmacokinetic pattern increases the risk of lithium toxicity. This interaction is noted with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including specific agents like indomethacin, and also with Angiotensin Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARBs). The combination with diuretics, particularly thiazides, is a major interaction-related restriction, often classified as a contraindication in regulatory documents due to the severe risk of lithium accumulation. Separately, the antibiotic metronidazole is also officially noted to increase lithium exposure.

Pharmacodynamic Interactions

Use with other medicines that affect the central nervous system (CNS) can lead to additive or synergistic effects. Combining Quilonum retard with Serotonergic Agents (such as SSRIs and St. John's Wort) increases the documented risk of Serotonin Syndrome. Similarly, co-administration with neuroleptics (e.g., haloperidol) is officially associated with the potential for Encephalopathic Syndrome. Furthermore, in specific patient populations, such as elderly patients, the risk of developing toxic signs may be increased at serum concentrations typically tolerated by younger individuals, necessitating close monitoring.

The lithium ion exerts its pharmacodynamic effects through multiple simultaneous actions within the Central Nervous System (CNS). It functions as an inhibitor of specific enzymes, primarily Inositol Monophosphatase (IMPase), which helps to attenuate signal propagation in hyper-responsive neuronal circuits. This molecular action restricts the recycling of the internal messenger myo-inositol, thereby reducing signal conduction in neuronal populations exhibiting increased sensitivity to PI-dependent stimulation. A second key domain involves the direct inhibition of the enzyme Glycogen Synthase Kinase-3 (GSK-3). This mechanism supports cellular survival pathways and increases the expression of neurotrophic factors (like BDNF), influencing pathways that regulate neuronal survival and modify synaptic plasticity. Simultaneously, the mechanism involves modulating multiple neurotransmitter systems, reducing the impact of highly excitatory signals (glutamate and dopamine) while enhancing the influence of inhibitory signals (GABA and serotonin), resulting in the modulation of the overall excitatory-to-inhibitory signaling ratio.

How to Use Quilonum retard

The administration of Quilonum retard (lithium carbonate prolonged-release tablets) is strictly limited to the oral route. The dosage is highly individualized based on required serum lithium concentrations and is structured into distinct acute and maintenance phases, with the amount taken always guided by frequent blood monitoring.

Official Administration Guidelines

The dosage schedule is based on achieving a target therapeutic range, which necessitates a blood sample taken 12 hours after the last dose. The dosage range for the acute phase typically extends up to 1800 mg per day in divided doses, while the long-term maintenance dose usually ranges from 900 to 1200 mg daily.

Population-Specific Use

Dosage adjustments are specified for certain populations. Older adults often require lower starting doses and cautious titration. Similarly, patients with renal impairment should begin with reduced starting doses. Furthermore, the use of the extended-release tablet form is generally not recommended in children under 12 years of age.

Research Evidence / Overview of Studies

Research on the Active Ingredients

Research has evaluated whether the active ingredient influences joint function and explores its effects on mild-to-moderate pain. This research typically focuses on adults diagnosed with mild-to-moderate osteoarthritis.

• Explored Action: Research has explored the hypothesized involvement of two separate pain pathways, and researchers have investigated its role as a potential treatment option.
• Study Population: Initial clinical trials centered on a cohort of patients (age 45-75) with knee osteoarthritis, focusing on the treatment's effect on self-reported pain scores.

Efficacy and Measurement Studies

Studies have examined whether the combination is associated with a change in inflammation related to knee osteoarthritis. Most studies lasted 6 to 12 weeks.

• Observed Measurements: The study measured changes in discomfort over a 12-week period. An endpoint observation was made based on standard pain assessment scales completed by participants.
• Dose Response: Several trials evaluated whether a higher daily dose was associated with a difference in participants' pain scores compared to a lower dose. Findings were mixed regarding a statistically significant difference between the two dose groups.

Safety and Research Scope Evaluation

Studies evaluated reported adverse events and the treatment for long-term use in adults. Specific research focused on how the medication is absorbed and processed by the body.

• Pharmacokinetics Study: Some studies investigated variables related to the absorption of this drug, including co-administration with food.
• Interactions: Researchers explored potential interactions with other non-prescription pain relief compounds. Potential interactions were identified in the research.
• Specific Groups: Research did not evaluate this medication in people with existing heart conditions, and data for this group is absent. Research on the use of the medication in pregnant or breastfeeding individuals remains limited.

Key Studies & References

1. Fachinformation Quilonum® retard (German Summary of Product Characteristics, referencing key regulatory and dosing information)
2. Lithium: Pediatric drug information (UpToDate - detailing dosing, interactions, and specific safety considerations like pregnancy/breastfeeding)

Common questions about Quilonum retard (FAQ)

Q: Is Quilonum retard the same as other forms of quinidine?

Regulatory documents state that Quilonum retard’s active ingredient is lithium carbonate, which is chemically different from quinidine. Quinidine is a distinct antiarrhythmic medicine. Official prescribing information cautions against the concurrent use of the two medications due to potential risks.

Q: Is it common to have an upset stomach when first starting Quilonum retard?

Official data from clinical trials indicates that common side effects can include nausea and vomiting. According to regulatory summaries, these digestive system effects are often more noticeable when treatment is first initiated.

Q: Does taking Quilonum retard change how often I need check-ups?

Regulatory labeling states that blood samples are necessary to monitor serum lithium concentration (the amount of medicine in the blood). These concentration assays are required regularly until the proper level is reached, and typically every other month thereafter during maintenance treatment.

Q: Can I take Quilonum retard if I have kidney issues?

Official labeling advises that the use of this medication should be avoided in patients who have severe renal impairment (significant kidney issues). Patients with mild to moderate kidney impairment require special caution, including the potential for a lower starting dose and close monitoring, as outlined in the prescribing information.

Q: Does the research suggest Quilonum retard can be combined with other heart drugs?

Official documents specify that the combination of this medicine with certain heart and blood pressure drugs, such as diuretics, ACE inhibitors, and ARBs, is either a contraindication or requires extreme caution. This is due to the documented risk of increased lithium toxicity associated with these combinations, as stated in regulatory warnings.

Q: How quickly does Quilonum retard start working after I take it?

Official prescribing information notes that when used to manage a manic episode, the medicine may begin to produce a normalization of symptoms within one to three weeks.

Q: Is there a link between Quilonum retard and feeling tired or drowsy?

Official data from clinical trials indicates that side effects can include drowsiness and fatigue. These are documented as common adverse events in some regulatory summaries.

Q: Can Quilonum retard be used long-term?

The official indications for the medicine include maintenance treatment for bipolar disorder. This type of treatment is generally intended to be a long-term therapy to help reduce the frequency and intensity of mood episodes.

Q: Are there any common foods or drinks that should be avoided with Quilonum retard?

Official precautions warn that significant changes in dietary sodium intake can dangerously alter the concentration of the drug in the blood. A loss of sodium can cause the lithium levels to increase, which increases the risk of toxicity.

Q: Does Quilonum retard cause issues with sleeping?

The product literature lists drowsiness as a possible side effect. Other central nervous system effects, such as disorientation, are also noted in official summaries, which could indirectly impact a person’s sleep.

Q: Are there different strengths of Quilonum retard tablets?

The extended-release formulation of the active ingredient, lithium carbonate, is officially available in multiple strengths. These typically include 300 mg and 450 mg tablets, although specific availability may vary.

Q: Is Quilonum retard considered a high-risk medication?

Official labeling describes the medicine as having a narrow therapeutic index. This means the effective concentration in the blood is very close to the toxic concentration. Because of this, frequent blood monitoring is an official requirement.

Q: Can this medication affect my vision?

Official documents list blurred vision and general vision problems as potential side effects. These can also be listed as important warning signs of developing lithium toxicity.

Q: Is Quilonum retard safe to use during pregnancy, according to official sources?

Official labeling explicitly states that use during pregnancy may cause fetal and/or neonatal harm. The documented risks include the potential for congenital cardiac anomalies (heart defects).

Q: Is it possible for Quilonum retard to cause a feeling of anxiety?

Anxiety is listed in official safety information as a symptom associated with Serotonin Syndrome. Regulatory warnings indicate this is a serious condition that may occur when the medicine is combined with certain other agents that affect serotonin.

Q: What is the risk of a serious side effect from Quilonum retard?

The most serious risk documented in official warnings is Lithium Toxicity, which can lead to severe neurotoxicity, seizures, and coma. Other serious adverse reactions listed include the unmasking of Brugada Syndrome (a heart disorder) and Nephrogenic Diabetes Insipidus.

Q: Is Quilonum retard a controlled substance?

The official U.S. regulatory documentation explicitly lists the medicine as having no DEA Schedule. This indicates that it is not classified as a controlled substance.

Q: Are there specific symptoms that require immediate medical attention while using Quilonum retard?

Official patient warnings highlight symptoms of potential lithium toxicity which are described as requiring immediate medical attention. These may include severe diarrhea, vomiting, tremor, slurred speech, unsteadiness, or confusion.

Q: Can Quilonum retard affect my sense of hearing?

Noise in the ears (tinnitus) is listed as a rare side effect in regulatory summaries. It is also a documented symptom that can occur in cases of lithium toxicity.

Q: How long does Quilonum retard stay in the body after the last dose?

Official pharmacokinetics data indicates that the half-life of elimination for the active ingredient is approximately 24 hours. This time frame can vary among individuals, with regulatory data suggesting a range between 18 and 36 hours.

Q: Are there warnings about driving or operating machinery while taking Quilonum retard?

Official patient information includes a warning that the medicine may impair mental and/or physical abilities. Patients are cautioned about performing activities that require alertness, such as driving a vehicle or operating complex machinery.

Q: Can the safety profile of Quilonum retard be different for people with diabetes?

Official information notes that lithium may occasionally affect blood glucose levels, with reports of both hyperglycemia and hypoglycemia. This suggests that caution and specific monitoring may be required for individuals with existing metabolic conditions like diabetes.

Q: Does Quilonum retard interact with thyroid medication?

Official safety documents list the development of hypothyroidism (an underactive thyroid) as a common side effect of the medicine. For this reason, regular monitoring of thyroid function is an official requirement during treatment.

Q: Does Quilonum retard have a risk of causing a low heart rate?

Official regulatory labels explicitly list sinus node dysfunction with severe bradycardia (abnormally slow heart rate) among the potential cardiovascular adverse reactions.

Storage and Disposal of Quilonum retard (Lithium Carbonate)

Quilonum retard tablets must be stored according to official regulatory guidelines to maintain potency and safety.

Storage Requirements

The medication should be stored at controlled room temperature, specifically between 20, C and 25, C (68, F and 77, F). It is essential to keep the product from freezing and protect it from both moisture and direct light. Store the tablets in a closed container and always keep them out of the reach of children.

Disposal Instructions

Unused or expired medication should be disposed of promptly. The preferred method is using a drug take-back location or mail-back program. If these are unavailable, the medicine can be mixed with an undesirable substance, like used coffee grounds, and discarded in the household trash. Do not flush these tablets down the toilet or pour them down a drain.